NOVA2在正常垂体与功能性和无功能性垂体腺瘤中的表达:初步研究
该初步研究用免疫组化检测12例垂体腺瘤(9例无功能性、3例功能性)和8例正常垂体组织中NOVA2的表达。NOVA2在两者内皮细胞中均有表达且腺瘤中更高,腺瘤细胞阳性而正常垂体上皮细胞阴性,功能性与无功能性腺瘤间无显著差异。提示NOVA2可能作为垂体腺瘤诊疗靶点。
要点
- NOVA2在垂体腺瘤细胞中表达,正常垂体上皮细胞不表达。
- NOVA2在腺瘤与正常垂体内皮细胞均表达,腺瘤中更高。
- 功能性与无功能性腺瘤间NOVA2表达无统计学显著差异。
核心结论
- 首次显示NOVA2表达于垂体腺瘤细胞而不表达于正常垂体上皮细胞,可能成为垂体腺瘤诊疗潜在靶点。
研究设计与样本
- 初步研究,收集12例垂体腺瘤患者(9例无功能性、3例功能性)和8例正常垂体组织样本,行免疫组化并以Histoscore半定量评估NOVA2表达。
主要发现
- NOVA2在垂体腺瘤和正常垂体的内皮细胞中均有表达,且腺瘤中表达更高。
- NOVA2在腺瘤细胞中表达,与腺瘤类型无关,而正常垂体上皮细胞NOVA2表达阴性。
- 功能性与无功能性垂体腺瘤之间NOVA2表达无统计学显著差异。
临床怎么用
- 现有垂体腺瘤药物治疗尤其对无功能性腺瘤疗效有限,NOVA2可能为诊断与治疗提供新靶点方向。
局限性
- 样本量小(12例腺瘤、8例正常垂体),为初步研究,需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Pituitary adenomas (PAs) are generally benign tumors with varying clinical presentations. While functioning PAs (FPAs) secrete hormones leading to distinct endocrine disorders, non-functioning PAs (NFPAs) often manifest with mass effect symptoms. Current medical therapies for PAs have limited efficacy, particularly for NFPAs. This highlights the need for new diagnostic and therapeutic targets. This study aimed to investigate the expression of Neuro-Oncological Ventral Antigen 2 (NOVA2), a factor involved in alternative splicing, in normal pituitary glands and PAs, to evaluate its potential as a novel therapeutic target. METHODS: Tissue samples from 12 PA patients (9 NFPAs and 3 FPAs) and 8 normal pituitary glands were collected. Immunohistochemical analysis was performed to assess NOVA2 expression. Semi-quantitative evaluation of NOVA2 staining was conducted using Histoscore. RESULTS: NOVA2 was expressed in the endothelial cells of both PAs and normal pituitary glands, with higher expression in PAs. Notably, NOVA2 was present in PA cells regardless of adenoma type, while normal pituitary epithelial cells were negative for NOVA2 expression. There was no statistically significant difference in NOVA2 expression between FPAs and NFPAs. CONCLUSIONS: This is the first study to demonstrate that NOVA2 is expressed in PA cells but not in normal pituitary epithelial cells. These findings suggest that NOVA2 could serve as a potential target for diagnostic and therapeutic strategies in PAs, especially considering the lack of specific biomarkers and effective medical therapies for these tumors. Further research with a larger sample size is warranted to validate these preliminary findings.
引用
- De Bonis P, Ghidoni F, Tisato V, et al. NOVA2 expression in pituitary gland and in functioning and non-functioning pituitary adenomas: a preliminary study. Acta Neurochir (Wien). 2025. PMID: 40549212. doi:10.1007/s00701-025-06576-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。